Clinical Trial Update: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial update for allogeneic P-BCMA-ALLO1 CAR-T cells in multiple myeloma; the study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• P-BCMA-ALLO1 (P-BCMA-ALLO1 CAR-T cells)

Snippet

Sponsor: Poseida Therapeutics, Inc. | Conditions: Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING